← Leaderboards
Bruce Alan Sullenger
Children'S Hosp Of Philadelphia
$24,141,070
Attributed
$27,932,324
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$39,043,839 · 18
By mechanism
R01$20,917,670 · 8
U54$11,568,540 · 2
P01$4,582,997 · 6
U19$1,582,132 · 1
R56$392,500 · 1
Top collaborators
- Richard Clinton Becker5 shared
- Kam W Leong5 shared
- Alice F Tarantal4 shared
- Rebekah White2 shared
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsAptamerCoagulation ProcessBaseAntidotesTherapeutic AgentsNovel StrategiesThrombosisAnimalsAnimal ModelAnticoagulantsIn VitroMouse ModelCombinatorial ChemistryFundingGenerationsBindingCellsHemorrhageOligonucleotidesSafetyIn VivoMediatingImmune Response
Grant awards (73)
Utilizing nucleic acid scavengers to elucidate how DNA/RNA-containing DAMPs promote pancreatic cancer metastasis and to mitigate such processes$638,056
R01 · FY2025 · CA · contact PI
RNA Aptamers as Probes and Modulators of Coagulation$501,865
P01 · FY2025 · HL · contact PI
Utilizing nucleic acid scavengers to elucidate how DNA/RNA-containing DAMPs promote pancreatic cancer metastasis and to mitigate such processes$656,237
R01 · FY2024 · CA · contact PI
RNA Aptamers as Probes and Modulators of Coagulation$547,400
P01 · FY2024 · HL · contact PI
Direct Detection and Characterization of Thrombosis In Vivo$734,488
R01 · FY2022 · HL
Engineering Polymers to Scavenge DAMPs in Arthritis and Lupus$656,459
R01 · FY2022 · AR · contact PI
Direct Detection and Characterization of Thrombosis In Vivo$734,488
R01 · FY2021 · HL
Engineering Polymers to Scavenge DAMPs in Arthritis and Lupus$647,211
R01 · FY2021 · AR · contact PI
Direct Detection and Characterization of Thrombosis In Vivo$734,488
R01 · FY2020 · HL
Engineering Polymers to Scavenge DAMPs in Arthritis and Lupus$671,248
R01 · FY2020 · AR · contact PI
RNA Aptamers as Probes and Regulators of Coagulation$468,145
P01 · FY2020 · HL · contact PI
Direct Detection and Characterization of Thrombosis In Vivo$748,088
R01 · FY2019 · HL
Engineering Polymers to Scavenge DAMPs in Arthritis and Lupus$672,596
R01 · FY2019 · AR · contact PI
RNA Aptamers as Probes and Regulators of Coagulation$401,316
P01 · FY2019 · HL · contact PI
Research Project 2: Nucleic acid scavengers-a novel radiation countermeasure$356,980
U19 · FY2019 · AI · contact PI
Engineering Polymers to Scavenge DAMPs in Arthritis and Lupus$689,149
R01 · FY2018 · AR · contact PI
Antithrombotic Aptamers and Antidotes$465,035
R01 · FY2018 · HL · contact PI
RNA Aptamers as Probes and Regulators of Coagulation$393,530
P01 · FY2018 · HL · contact PI
Research Project 2: Nucleic acid scavengers-a novel radiation countermeasure$304,250
U19 · FY2018 · AI · contact PI
Antithrombotic Aptamers and Antidotes$466,759
R01 · FY2017 · HL · contact PI
Research Project 2: Nucleic acid scavengers-a novel radiation countermeasure$368,043
U19 · FY2017 · AI · contact PI
GENERATION OF A MODEL OF HEMOPHILIA B IN AAV RESISTANT PRIMATES$186,218
P01 · FY2017 · HL · contact PI
GENERATION OF A MODEL OF HEMOPHILIA B IN AAV RESISTANT PRIMATES$186,216
P01 · FY2017 · HL · contact PI
DTMI-Center for Thrombotic and Hemostatic Disorders$2,215,887
U54 · FY2016 · HL · contact PI
Antithrombotic Aptamers and Antidotes$466,759
R01 · FY2016 · HL · contact PI
Research Project 2: Nucleic acid scavengers-a novel radiation countermeasure$284,695
U19 · FY2016 · AI · contact PI
GENERATION OF A MODEL OF HEMOPHILIA B IN AAV RESISTANT PRIMATES$188,279
P01 · FY2016 · HL · contact PI
GENERATION OF A MODEL OF HEMOPHILIA B IN AAV RESISTANT PRIMATES$188,279
P01 · FY2016 · HL · contact PI
DTMI-Center for Thrombotic and Hemostatic Disorders$2,213,927
U54 · FY2015 · HL · contact PI
Antithrombotic Aptamers and Antidotes$481,509
R01 · FY2015 · HL · contact PI
Research Project 2: Nucleic acid scavengers-a novel radiation countermeasure$268,164
U19 · FY2015 · AI · contact PI
GENERATION OF A MODEL OF HEMOPHILIA B IN AAV RESISTANT PRIMATES$187,349
P01 · FY2015 · HL · contact PI
GENERATION OF A MODEL OF HEMOPHILIA B IN AAV RESISTANT PRIMATES$187,347
P01 · FY2015 · HL · contact PI
DTMI-Center for Thrombotic and Hemostatic Disorders$2,269,092
U54 · FY2014 · HL · contact PI
GENERATION OF A MODEL OF HEMOPHILIA B IN AAV RESISTANT PRIMATES$185,479
P01 · FY2014 · HL · contact PI
GENERATION OF A MODEL OF HEMOPHILIA B IN AAV RESISTANT PRIMATES$185,475
P01 · FY2014 · HL · contact PI
DTMI-Center for Thrombotic and Hemostatic Disorders$2,206,682
U54 · FY2013 · HL · contact PI
Antithrombotic Aptamers and Antidotes$489,908
R01 · FY2013 · HL · contact PI
GENERATION OF A MODEL OF HEMOPHILIA B IN AAV RESISTANT PRIMATES$398,440
P01 · FY2013 · HL · contact PI
DTMI-Center for Thrombotic and Hemostatic Disorders$2,205,927
U54 · FY2012 · HL
Antithrombotic Aptamers and Antidotes$514,609
R01 · FY2012 · HL · contact PI
RNA aptamers as cell surface receptor agonists and siRNA delivery agents$251,191
R01 · FY2012 · CA · contact PI
Antithrombotic Aptamers and Antidotes$514,616
R01 · FY2011 · HL · contact PI
Nucleic Acid Binding Polymers as Anti-Inflammatory Agents$392,500
R56 · FY2011 · AI · contact PI
RNA aptamers as cell surface receptor agonists and siRNA delivery agents$251,191
R01 · FY2011 · CA · contact PI
Antithrombotic Aptamers and Antidotes$536,960
R01 · FY2010 · HL · contact PI
RNA aptamers as cell surface receptor agonists and siRNA delivery agents$258,960
R01 · FY2010 · CA · contact PI
RNA aptamers as cell surface receptor agonists and siRNA delivery agents$258,960
R01 · FY2009 · CA · contact PI
Development and Analysis of Aptamer-Antidote Pairs$586,302
R01 · FY2008 · HL · contact PI
Development and Analysis of Aptamer-Antidote Pairs$581,704
R01 · FY2007 · HL · contact PI
Ribozyme-Mediated Repair of Sickle Beta-Globin RNA and DNA$295,953
U54 · FY2007 · HL · contact PI
Development and Analysis of Aptamer-Antidote Pairs$582,061
R01 · FY2006 · HL · contact PI
E2F-mediated Control of Vascular Growth and Remodeling$440,708
R01 · FY2006 · HL · contact PI
Ribozyme-Mediated Repair of Sickle Beta-Globin RNA and DNA$161,072
U54 · FY2006 · HL · contact PI
Development and Analysis of Aptamer-Antidote Pairs$579,154
R01 · FY2005 · HL
E2F-mediated Control of Vascular Growth and Remodeling$440,050
R01 · FY2005 · HL
Analysis of Group I and II Introns in Mammalian Cells$319,100
R01 · FY2005 · GM
E2F, INTIMAL HYPERPLASIA$251,436
P01 · FY2005 · GM
Development and Analysis of Aptamer-Antidote Pairs$576,986
R01 · FY2004 · HL
E2F-mediated Control of Vascular Growth and Remodeling$429,033
R01 · FY2004 · HL
DISRUPTING VIRAL GENES WITH GROUP II INTRONS$356,002
R01 · FY2004 · GM
Analysis of Group I and II Introns in Mammalian Cells$319,100
R01 · FY2004 · GM
E2F-mediated Control of Vascular Growth and Remodeling$416,538
R01 · FY2003 · HL
DISRUPTING VIRAL GENES WITH GROUP II INTRONS$346,799
R01 · FY2003 · GM
Analysis of Group I and II Introns in Mammalian Cells$319,100
R01 · FY2003 · GM
IDENTIFYING NOVEL HEMOSTATIC PROTEINS$269,500
R01 · FY2003 · HL
DISRUPTING VIRAL GENES WITH GROUP II INTRONS$337,864
R01 · FY2002 · GM
Analysis of Group I and II Introns in Mammalian Cells$331,296
R01 · FY2002 · GM
IDENTIFYING NOVEL HEMOSTATIC PROTEINS$269,500
R01 · FY2002 · HL
DISRUPTING VIRAL GENES WITH GROUP II INTRONS$342,688
R01 · FY2001 · GM
IDENTIFYING NOVEL HEMOSTATIC PROTEINS$269,500
R01 · FY2001 · HL
IDENTIFYING NOVEL HEMOSTATIC PROTEINS$265,720
R01 · FY2000 · HL
SYSTEMATIC DEVELOPMENT OF IMPROVED RNA INHIBITORS OF HIV$126,223
P01 · FY2000 · AI